Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT)

Galectin Therapeutics Inc. (NASDAQ:GALT) was the recipient of unusually large options trading activity on Monday. Stock investors bought 14,331 put options on the stock. This represents an increase of 557% compared to the average volume of 2,182 put options.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a research report on Friday, November 15th. StockNews.com raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th.

Institutional Trading of Galectin Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of GALT. Marshall Wace LLP acquired a new position in Galectin Therapeutics in the 2nd quarter worth $43,000. Rhumbline Advisers acquired a new position in shares of Galectin Therapeutics in the 2nd quarter valued at about $44,000. Gladstone Institutional Advisory LLC bought a new position in shares of Galectin Therapeutics during the third quarter valued at approximately $60,000. Barclays PLC grew its stake in Galectin Therapeutics by 309.0% during the 3rd quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after buying an additional 21,598 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC acquired a new stake in shares of Galectin Therapeutics in the 3rd quarter worth about $117,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Stock Performance

Shares of NASDAQ:GALT opened at $2.12 on Wednesday. Galectin Therapeutics has a one year low of $1.55 and a one year high of $4.27. The company has a 50-day simple moving average of $2.57 and a 200-day simple moving average of $2.51. The stock has a market capitalization of $133.06 million, a price-to-earnings ratio of -2.90 and a beta of 0.69.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.